SAN CARLOS, Calif. (PRWEB) September 22, 2020
ZAP Surgical Systems, Inc. today announced ZAP-X® Gyroscopic Radiosurgery® patient treatments have commenced at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center in Clinton, MD.
For many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) has proven to be an effective treatment with outcomes equivalent to invasive surgical procedures. Unlike surgery however, SRS is a non-invasive outpatient procedure with no surgical incision and often requires little to no patient recovery period.
“Radiosurgery is among the most important innovations in modern medicine for the treatment of many brain tumors,” said Dr. Adler, CEO of ZAP Surgical Systems, and professor emeritus of neurosurgery and radiation oncology at Stanford University. “With ZAP-X, patients can be treated without the potential complications and recovery of a surgical procedure.”
The new ZAP-X technology is recognized for using gyroscopic motion to direct radiosurgical beams from hundreds of unique angles to precisely concentrate radiation to the tumor target. With this unique approach, radiation doses rapidly dissipate beyond the tumor to mitigate potential toxicities to adjacent healthy brain tissue.
ZAP-X is also the first and only dedicated radiosurgery system which does not require live radioactive sources, thus significantly reducing hospital costs while also eliminating heightened security requirements.
“MedStar Health is long renowned for offering world-class cancer care,” added Dr. Adler, “We are honored to partner with their clinical team to bring this potentially life-saving therapy to southern Maryland and the surrounding area.”
About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery™ platform. ZAP was founded in 2014 by John R. Adler, MD, professor emeritus of neurosurgery and radiation oncology at Stanford University, and CEO of ZAP Surgical Systems. Dr. Adler is also the inventor of the CyberKnife® and founder of Accuray, Inc. FDA-cleared in September 2017, ZAP-X utilizes a modern linear accelerator to eliminate the historical use of Cobalt-60 and the related costs and challenges of handling live radioactive isotopes. ZAP-X also incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. Learn more at http://www.zapsurgical.com.
Senior Vice President, Marketing
ZAP Surgical Systems, Inc.